The Italian biotech company MolMed SpA is withdrawing its cell therapy for use in transplantation procedures, Zalmoxis, from the market. Announcing the decision on 10 October, the company said the decision had been taken “for commercial reasons.”
Zalmoxis (allogeneic genetically modified T cells) was approved for reimbursement in Italy in 2017. It was not immediately clear whether the product was being financially supported by any other European healthcare authorities.